Kissei Pharmaceutical Co., Ltd.
Other OTCTotal Valuation
Kissei Pharmaceutical Co., Ltd. carries a market capitalization of 1.07B, placing it among publicly traded companies globally. Its enterprise value stands at 111.25B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.07B |
| Enterprise Value | 111.25B |
Share Statistics
Kissei Pharmaceutical Co., Ltd. currently has 44.21M shares outstanding.
| Shares Outstanding | 44.21M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Kissei Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 28.98. The price-to-sales ratio is 4.11, and the price-to-book ratio stands at 1.02.
| PE Ratio | 28.98 |
| PS Ratio | 4.11 |
| PB Ratio | 1.02 |
| P/TBV Ratio | 0.73 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Kissei Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 55.60 and an EV/FCF ratio of 15,520.78. The EV/Sales ratio of 2.88 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 55.60 provides insight into valuation relative to core operating earnings.
| EV / Sales | 2.88 |
| EV / EBITDA | 55.60 |
| EV / EBIT | 55.60 |
| EV / FCF | 15,520.78 |
Financial Position
Kissei Pharmaceutical Co., Ltd. maintains a current ratio of 5.50, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.57, indicating moderate leverage, while an interest coverage ratio of 222.33 demonstrates strong ability to service its debt obligations.
| Current Ratio | 5.50 |
| Quick Ratio | 2.57 |
| Debt / Equity | 0.57 |
| Debt / EBITDA | 0.63 |
| Interest Coverage | 222.33 |
Financial Efficiency
Kissei Pharmaceutical Co., Ltd. posts a return on equity of 3.62 and a return on invested capital of 0.74.
| Return on Equity (ROE) | 3.62 |
| Return on Assets (ROA) | 2.23 |
| Return on Invested Capital (ROIC) | 0.74 |
| Return on Capital Employed (ROCE) | 3.53 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.77 |
Taxes
Over the trailing twelve months, Kissei Pharmaceutical Co., Ltd. has paid 1.41B in income taxes, reflecting an effective tax rate of 20.35.
| Income Tax | 1.41B |
| Effective Tax Rate | 20.35 |
Stock Price Statistics
Kissei Pharmaceutical Co., Ltd.'s stock has declined approximately -5.0129% over the past 52 weeks. The 50-day moving average sits at 25.77, while the 200-day moving average is 27.22.
| Beta (5Y) | N/A |
| 52-Week Price Change | -5.0129% |
| 50-Day Moving Average | 25.77 |
| 200-Day Moving Average | 27.22 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Kissei Pharmaceutical Co., Ltd. generated 38.60B in revenue and converted that into 5.48B in net income, yielding earnings per share of 125.17. EBITDA reached 2.00B, while operating income came in at 2.00B.
| Revenue | 38.60B |
| Gross Profit | 19.04B |
| Operating Income | 2.00B |
| Pretax Income | 6.95B |
| Net Income | 5.48B |
| EBITDA | 2.00B |
| EBIT | 2.00B |
| Earnings Per Share (EPS) | 125.17 |
Balance Sheet
Kissei Pharmaceutical Co., Ltd. holds 49.96B in cash and equivalents against 1.26B in total debt, resulting in a net debt position of -25.18B. Total book value stands at 155.10B, with working capital of 87.56B providing operational flexibility.
| Cash & Cash Equivalents | 49.96B |
| Total Debt | 1.26B |
| Net Debt | -25.18B |
| Equity (Book Value) | 155.10B |
| Book Value Per Share | 3,508.89 |
| Working Capital | 87.56B |
Margins
Kissei Pharmaceutical Co., Ltd. operates with a gross margin of 49.33, reflecting its pricing power and cost economics. The operating margin of 5.18 and net profit margin of 14.20 provide insight into operational efficiency.
| Gross Margin | 49.33 |
| Operating Margin | 5.18 |
| Pretax Margin | 18.00 |
| Profit Margin | 14.20 |
| EBITDA Margin | 5.18 |
Scores
Kissei Pharmaceutical Co., Ltd. posts an Altman Z-Score of 3.70, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.70 |